文献速递白血病

卡非佐米通过抑制ELK1/KIAA1524(Elk-1/CIP2A)并激活PP2A诱导白血病细胞凋亡,与蛋白酶体抑制无关

Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
PubMed 文献 · Br J Haematol · 2017-03-24

研究显示,选择性蛋白酶体抑制剂卡非佐米可在敏感的原代白血病细胞和敏感白血病细胞系中诱导凋亡,伴随KIAA1524蛋白下调、PP2A活性升高和p-Akt降低,且该效应与其蛋白酶体抑制作用无关。机制上,卡非佐米通过干扰ELK1与KIAA1524启动子结合影响KIAA1524转录;异种移植小鼠模型中的药物敏感性和机制与体外对KIAA1524、p-Akt及PP2A活性的影响一致。

要点

  • 卡非佐米在敏感白血病细胞中诱导凋亡,伴KIAA1524下调、PP2A活性升高和p-Akt降低。
  • 该凋亡诱导效应与卡非佐米的蛋白酶体抑制作用无关。
  • 卡非佐米通过干扰ELK1与KIAA1524启动子结合影响KIAA1524转录。

核心结论

  • 卡非佐米在白血病细胞中通过抑制ELK1/KIAA1524并激活PP2A诱导凋亡,该机制与蛋白酶体抑制无关,提示KIAA1524在白血病治疗中具有潜在治疗意义。

研究设计与样本

  • 研究使用敏感的原代白血病细胞和敏感白血病细胞系,以及异种移植小鼠模型。

主要发现

  • 卡非佐米在敏感的原代白血病细胞和敏感白血病细胞系中诱导凋亡,伴随KIAA1524蛋白下调、PP2A活性升高和p-Akt降低,但与卡非佐米的蛋白酶体抑制效应无关。
  • 在敏感细胞中,KIAA1524的异位表达或PP2A抑制剂冈田酸预处理可抑制卡非佐米诱导的凋亡和KIAA1524下调;而在耐药细胞中,PP2A激动剂佛司可林共处理可增强卡非佐米诱导的凋亡。
  • 机制上,卡非佐米通过干扰ELK1与KIAA1524启动子结合影响KIAA1524转录。
  • 在异种移植小鼠模型中,卡非佐米的药物敏感性和机制与其对KIAA1524和p-Akt表达以及PP2A活性的影响一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enhancing the tumour suppressive activity of protein phosphatase 2A (PP2A) has been suggested to be an anti-leukaemic strategy. KIAA1524 (also termed CIP2A), an oncoprotein inhibiting PP2A, is associated with disease progression in chronic myeloid leukaemia and may be prognostic in cytogenetically normal acute myeloid leukaemia. Here we demonstrated that the selective proteasome inhibitor, carfilzomib, induced apoptosis in sensitive primary leukaemia cells and in sensitive leukaemia cell lines, associated with KIAA1524 protein downregulation, increased PP2A activity and decreased p-Akt, but not with the proteasome inhibition effect of carfilzomib. Ectopic expression of KIAA1524, or pretreatment with the PP2A inhibitor, okadaic acid, suppressed carfilzomib-induced apoptosis and KIAA1524 downregulation in sensitive cells, whereas co-treatment with the PP2A agonist, forskolin, enhanced carfilzomib-induced apoptosis in resistant cells. Mechanistically, carfilzomib affected KIAA1524 transcription through disturbing ELK1 (Elk-1) binding to the KIAA1524 promoter. Moreover, the drug sensitivity and mechanism of carfilzomib in xenograft mouse models correlated well with the effects of carfilzomib on KIAA1524 and p-Akt expression, as well as PP2A activity. Our data disclosed a novel drug mechanism of carfilzomib in leukaemia cells and suggests the potential therapeutic implication of KIAA1524 in leukaemia treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liu CY, Hsieh FS, Chu PY, et al. Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition. Br J Haematol. 2017. PMID: 28340282. doi:10.1111/bjh.14620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。